Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Could one of these biotech takeover candidates be the next target?
The analysts at UBS are not only bullish on the biotechnology sector, they think there is a very distinct possibility that some of the top names may also become takeover targets this…
Finviz.comWith the end of the year two weeks away, 10Â stocks have already had gains of more than 400%. Investors in these stocks have been, if they held them for the year, wildly…
ThinkstockEven though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report that the…
